Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy

NCT03039686 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT03039686
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03039686 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2/3
Overall status
Completed
Start date
July 6, 2017
Completion date
April 28, 2020
Enrollment
166 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy